COST EFFECTIVENESS ANALYSIS OF ORAL IRON CHELATING DRUGS BETWEEN DEFERIPRONE AND DEFERASIROX IN THALASEMIA MAJOR PATIENTS AT BHAYANGKARA SETUKPA LEMDIKLAT POLRI TK.II HOSPITAL.

Thalassemia is a blood disorder that results from decreased or lost synthesis of one or more globin chains. Thalassemia major as a red blood cell disorder requires high costs because it requires blood transfusions and the use of iron chelation drugs throughout the patient's life. This study aims to analyze the cost and effectiveness of oral iron chelation drugs such as deferasirox and deferiprone in patients with Thalassemia major at Setukpa Lemdiklat Polri Tk--II Hospital in 2023. Data was collected retrospectively using total sampling from patient medical records and hospital information system data. Based on the results of this study, the average total cost per treatment for thalassemia major patients who used deferasirox (IDR 52,969,775,-) was more expensive than deferiprone (IDR 49,407,613,-). The effectiveness of deferasirox (1,364 ng/mL) was bigger than that of deferiprone (1,210 ng/mL). The cost-effectiveness ratio of deferasirox (IDR 38,834,-) was lower than that of deferiprone (IDR 40,833,-). To change the drug from deferiprone to deferasirox requires an additional cost of IDR 23,130 per one additional unit. From the average costeffectiveness ratio, it can be concluded that deferasirox is more cost-effective than deferiprone. [ABSTRACT FROM AUTHOR]